Results 31 to 40 of about 34,871 (236)
Регуляторные исследования и экспертиза лекарственных средств, 2021 Radiopharmaceuticals differ from other medicines mainly by the specific nature of their pharmacological action based on radioactivity, by absence of multiple-dose regimens, and by miniscule concentrations of the active pharmaceutical ingredient (10-9–10 ...
O. E. Klementyeva +2 more
doaj +1 more source
Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic [PDF]
, 2023 Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot ...
Craig W. Lindsley (1327038) +2 more
core +3 more sources
Radiopharmaceuticals Used in Molecular Imaging [PDF]
, 2021 Molecular imaging technology can be used for many applications, including drug development, clinical investigations,and diagnostic techniques. Molecular imaging techniques depend upon molecular mechanisms operating in vivo.
Ekinci, Meliha +2 more
core +2 more sources
Research Progress of Metal-Based Radiopharmaceuticals Targeting Somatostatin Receptor
He huaxue yu fangshe huaxue, 2023 Neuroendocrine tumors(NETs) are a group of heterogeneous tumors originating from neuroendocrine cells. They can occur anywhere in the body, most commonly in the digestive tract, pancreas, and lungs.
QIN Xiang-yu, SHEN Lang-tao
doaj +1 more source
Radiopharmaceutical Therapy [PDF]
Health Physics, 2019 Abstract Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, peptides, and small molecules) or that concentrate in tumors through natural physiological mechanisms that occur predominantly in neoplastic cells.
openaire +2 more sources
Preparation of radiopharmaceuticals labeled with metal radionuclides [PDF]
, 1992 We recently developed a useful zinc-62/copper-62 generator and are presently evaluating copper-62 radiopharmaceuticals for clinical studies. While developing these copper-62 radiopharmaceuticals, in collaboration with the University of Missouri Research ...
Welch, M. J.
core +1 more source
Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi +19 more
wiley +1 more source
Radiopharmaceuticals to in vivo characterize adrenal incidentalomas: the integrated role of radionuclide and radiological techniques. [PDF]
, 2008 To illustrate the role of radiopharmaceuticals in characterizing non-hypersecreting adrenal masses, 56 patients with non-hypersecreting unilateral adrenal tumors detected on CT and/or MR underwent adrenal scintigraphy.
MAUREA, SIMONE, SALVATORE, MARCO
core +3 more sources
mAbs, 2023 Monoclonal antibody (mAb) production using non-human cells can introduce non-human glycan epitopes including terminal galactosyl-α1–3-galactose (α1–3-Gal) moieties. Cetuximab is a commercial mAb associated with causing anaphylaxis in some patients due to
Grayson Hatfield +5 more
doaj +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source